Related Experiment Video
Updated: Mar 27, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic viruses: finally delivering
Leonard W Seymour1, Kerry D Fisher1
1Department Oncology, University of Oxford, Oxford OX3 7DQ, UK.
Abstract:
Oncolytic viruses can be found at the confluence of virology, genetic engineering and pharmacology where versatile platforms for molecularly targeted anticancer agents can be designed and optimised. Oncolytic viruses offer several important advantages over traditional approaches, including the following. (1) Amplification of the active agent (infectious virus particles) within the tumour. This avoids unnecessary exposure to normal tissues experienced during delivery of traditional stoichiometric chemotherapy and maximises the therapeutic index. (2) The active cell-killing mechanisms, often independent of programmed death mechanisms, should decrease the emergence of acquired drug resistance. (3) Lytic death of cancer cells provides a pro-inflammatory microenvironment and the potential for induction of an anticancer vaccine response. (4) Tumour-selective expression and secretion of encoded anticancer biologics, providing a new realm of potent and cost-effective-targeted therapeutics.
Insights
Oncolytic viruses offer targeted cancer therapy by amplifying within tumors, reducing side effects. They also enhance immune response and deliver targeted therapeutics, improving cancer treatment outcomes.
Area of Science:
- Virology
- Genetic Engineering
- Pharmacology
Background:
- Oncolytic viruses represent a versatile platform for developing molecularly targeted anticancer agents.
- Traditional chemotherapy exposes normal tissues, limiting the therapeutic index.
Purpose of the Study:
- To highlight the advantages of oncolytic viruses as anticancer agents.
- To explore their potential in cancer treatment.
Main Methods:
- The study discusses the inherent properties and mechanisms of oncolytic viruses.
- It reviews their application in designing targeted anticancer therapies.
Main Results:
- Oncolytic viruses amplify within tumors, maximizing therapeutic index and minimizing exposure to normal tissues.
- Their cell-killing mechanisms reduce drug resistance, and lysis induces an anti-cancer immune response.
- Tumor-selective expression of biologics offers potent, cost-effective targeted therapeutics.
Conclusions:
- Oncolytic viruses provide a promising therapeutic strategy with multiple advantages over conventional treatments.
- Further development can lead to potent and cost-effective targeted cancer therapies.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
Tumor Immunotherapy
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

